Search Results - "Yassin, Mohamad A."

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Eltrombopag Can Achieve Treatment Free Remission as Upfront Therapy for Patient with Immune Thrombocytopenia by Obeidat, Khaldun, Yassin, Mohamad A

    “…Immune Thrombocytopenic purpura (ITP) is an immune mediated thrombocytopenia caused by autoantibodies directed against platelet antigens which leads to…”
    Get full text
    Journal Article
  2. 2

    Low-Dose Eltrombopag in a Patient with Chronic Idiopathic Thrombocytopenic Purpura Post Sleeve Gastrectomy by Ahmed, Mohanad A., Yassin, Mohamad A.

    Published in Case reports in oncology (15-06-2020)
    “…Idiopathic thrombocytopenic purpura (ITP) is a disease in which the immune system attacks platelets and causes decrease in its number exposing the patient to…”
    Get full text
    Journal Article
  3. 3

    Chronic myelogenous leukemia presenting with Morel Lavallée lesion: A case report of a rare presentation by Mohamed, Sara S. I., Qasim, Hana Mahmoud, Mahfouz, Ahmed, Osman, Maab A., Ahmed, Ashraf O. E., Al‐Azewi, Safa H., Yassin, Mohamad A., Fareed, Shehab

    Published in Clinical case reports (01-12-2022)
    “…Chronic myelogenous leukemia is a myeloproliferative neoplasm characterized by the BCR‐ABL1 fusion gene and the development of the Philadelphia chromosome,…”
    Get full text
    Journal Article
  4. 4

    Immune thrombocytopenia relapse post covid-19 vaccine in young male patient by Qasim, Hana, Ali, Elrazi, Yassin, Mohamad A.

    Published in IDCases (01-01-2021)
    “…Immune thrombocytopenic purpura (ITP) is a blood disorder in which antibodies coating platelets cause platelets destruction in the spleen with resultant low…”
    Get full text
    Journal Article
  5. 5

    Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature by Kassem, Nancy, Ismail, Omar M, Elomri, Halima, Yassin, Mohamad A

    Published in The American journal of case reports (14-07-2017)
    “…BACKGROUND Tyrosine kinase inhibitors (TKIs) are currently an important targeted drug class in the treatment of chronic myeloid leukemia (CML). Imatinib was…”
    Get full text
    Journal Article
  6. 6
  7. 7